Modified Delphi survey for the evidence summarisation of patient decision AIDS: Study protocol by Durand, Marie Anne et al.
Bond University
Research Repository
Modified Delphi survey for the evidence summarisation of patient decision AIDS
Durand, Marie Anne; Dannenberg, Michelle D.; Saunders, Catherine H.; Giguere, Anik M.C.;
Alper, Brian S.; Hoffmann, Tammy; Perestelo-Pérez, Lily; Campbell, Stephen T.; Elwyn, Glyn
Published in:
BMJ Open
DOI:
10.1136/bmjopen-2018-026701
10.1136/bmjopen-2018-026701
Published: 01/03/2019
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Durand, M. A., Dannenberg, M. D., Saunders, C. H., Giguere, A. M. C., Alper, B. S., Hoffmann, T., ... Elwyn, G.
(2019). Modified Delphi survey for the evidence summarisation of patient decision AIDS: Study protocol. BMJ
Open, 9(3), [026701]. https://doi.org/10.1136/bmjopen-2018-026701, https://doi.org/10.1136/bmjopen-2018-
026701
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 09 Jul 2019
1Durand M-A, et al. BMJ Open 2019;9:e026701. doi:10.1136/bmjopen-2018-026701
Open access 
Modified Delphi survey for the 
evidence summarisation of patient 
decision aids: Study protocol
Marie-Anne Durand,1 Michelle D Dannenberg,1 Catherine H Saunders,1 
Anik M C Giguere,2 Brian S Alper,  3,4 Tammy Hoffmann,5 Lily Perestelo-Pérez,6 
Stephen T Campbell,7 Glyn Elwyn8
To cite: Durand M-A, 
Dannenberg MD, Saunders CH, 
et al.  Modified Delphi survey 
for the evidence summarisation 
of patient decision aids: 
Study protocol. BMJ Open 
2019;9:e026701. doi:10.1136/
bmjopen-2018-026701
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
026701).
Received 24 September 2018
Revised 6 February 2019
Accepted 12 February 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Marie-Anne Durand;  
 marie- anne. durand@ dartmouth. 
edu
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Information included in a patient decision 
aid (PDA) can significantly influence patients’ decisions 
and is, therefore, expected to be evidence-based and 
rigorously selected and summarised. PDA developers have 
not yet agreed on a standardised process for the selection 
and summarisation of the supporting evidence. We intend 
to generate consensus on a process (and related steps and 
criteria) for selecting and summarising evidence for PDAs 
using a modified Delphi survey.
Methods and analysis We will develop an evidence 
summarisation process specific to PDA development by 
using a consensus-based Delphi approach, surveying 
international experts and stakeholders with two to three 
rounds. To increase generalisability and acceptability, 
we will distribute the survey to the following stakeholder 
groups: PDA developers, researchers with expertise in 
shared decision making, PDA development and evidence 
summarisation, members of the International Patient 
Decision Aids Standards (IPDAS) collaboration, policy 
makers with expertise in PDA certification and patient 
stakeholder groups. For each criterion, if at least 80% of 
survey participants rank the criterion as most important/
least important, we will consider that consensus has been 
achieved.
Ethics and dissemination It is critical for PDAs to have 
accurate and trustworthy evidence-based information 
about the risks and benefits of health treatments 
and tests, as these decision aids help patients make 
important choices. We want to generate consensus on 
an approach for selecting and summarising the evidence 
included in PDAs, which can be widely implemented by 
PDA developers. Dartmouth College’s Committee for the 
Protection of Human Subjects approved this protocol. We 
will publish our results in a peer reviewed journal.
IntroduCtIon 
Patient decision aids (PDAs) are tools that 
help patients and their clinicians make pref-
erence-sensitive decisions together. They are 
typically defined as ‘evidence‐based tools 
designed to help patients make specific 
and deliberated choices among health-
care options. PDAs supplement (rather 
than replace) clinicians' counselling about 
options’.1 2 They promote patient engage-
ment in medical decision-making, collab-
oration between patients and their care 
team, increase knowledge and align patients’ 
choices with their preferences.1 Therefore, 
the information included in PDAs can signifi-
cantly impact patients’ decisions. For this 
reason, patients and clinicians expect the 
information in PDAs to be evidence-based 
and rigorously selected and summarised.
The approach that PDA developers use to 
select and summarise the evidence in PDAs, 
however, appears inconsistent. A recent inter-
national cross-sectional survey of 15 PDA 
developers confirms that they do not have an 
agreed-upon, standardised process to select 
and summarise evidence. They also do not 
always document the evidence selection and 
summarisation process.3 Most organisations 
reported using existing systematic reviews 
and clinical practice guidelines to select and 
summarise information for PDAs. Less than 
half reported using a standard, documented 
approach to guide the evidence selection and 
summarisation. When the approach was docu-
mented, the documents offered varying levels 
of detail. Common evidence summarisation 
strengths and limitations of this study
 ► Gap: There is no standardised method for selecting 
and summarising the evidence in   patient decision 
aids (PDAs).
 ► Solution: We are developing a process to ensure 
PDAs have the most up-to-date, trustworthy evi-
dence available.
 ► Clinical implications: This will help patients and cli-
nicians know they can trust the information in PDAs 
so they can make the best decisions together.
 ► Strengths: Systematic involvement of patient 
stakeholders.
 ► Limitations: Limitations of online surveys include 
selection bias.
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steps identified were: tool-relevant question formation, 
search strategies, evidence appraisals and updating policies. 
There was no standardised process across organisations 
to summarise evidence for PDAs. Although agreed-upon 
approaches and tested methods for evidence summari-
sation, such as clinical practice guidelines , exist in other 
areas, there is no agreed process (including steps and 
criteria within each step) for the selection and summarisa-
tion of evidence for PDAs.
The International Patient Decision Aids Standards 
(IPDAS) collaboration developed criteria for assessing 
the quality of PDAs.4 These criteria are also used by PDA 
producers to guide the development of the interventions. 
However, only six items of the IPDAS checklist cover the 
selection and summarisation of evidence, and do not 
provide any guidance about recommended methods 
for evidence selection and summarisation of PDAs.4 A 
2013 review of the literature conducted by the IPDAS 
working group on the synthesis of scientific evidence 
highlighted the importance of rigorously selecting and 
summarising evidence used to populate a PDA. They did 
not provide clear practical guidance on how to conduct 
evidence summarisation for the development of PDAs 
except recommending that developers apply the Grading 
of Recommendations Assessment, Development and 
Evaluation (GRADE) methodology.5 Further, the IPDAS 
instrument and the IPDAS minimum standards do not 
offer additional information or guidance on the steps 
required to select and summarise evidence-based infor-
mation for PDAs.6 7 Other efforts to evaluate or certify 
the quality of PDAs have emerged,8 but none of those 
standards or certification bodies describe recommended 
methods and criteria that PDA producers should follow 
when selecting and summarising evidence for patient-
facing interventions.
Evidence summarisation in other medical contexts, 
such as the selection and summariation of evidence for 
clinical practice guidelines and systematic reviews, is 
increasingly standardised. This process promotes trans-
parency, rigour and minimises the risk of bias in the end 
product.2 9–17 The same level of scrutiny is justified when 
developing PDAs, as they may directly influence patient 
care and decision-making. Tasks such as the selection 
and identification of patient-relevant outcomes, analysis 
of patient concerns and priorities, description of the 
quality of evidence and communication of uncertainty in 
ways that patients understand, warrants the development 
of an agreed process and related steps and criteria that 
are specific to PDAs. For these reasons, it would not be 
appropriate to apply evidence summarisation processes 
developed for clinical guidelines without integrating the 
evidence summarisation steps and components that are 
specific to the development of interventions that target 
patients. The target group, scope and content differ 
significantly enough from clinical practice guidelines 
development, thus requiring a tailored evidence summari-
sation process. Additionally, the IPDAS impose some 
prerequisites on the evidence summarisation process on 
which the decision aid will be based. For example, IPDAS 
requires that the decision aid summarise the evidence 
regarding all health options available to a patient facing 
a specific health problem, and that decision aids present 
positive and negative features of each option with equal 
amount of details, among other specificities.18 Efforts to 
develop an agreed evidence summarisation process for 
PDAs should incorporate the substantial body of related 
evidence summarisation guidance previously developed 
by other groups, and notably for clinical practice guide-
lines previously mentioned.11
objective
The purpose of the study is to generate consensus on a 
process (and related steps and criteria) for selecting and 
summarising evidence for PDAs using a modified Delphi 
survey. This will in turn improve transparency, rigour and 
minimise the risk of bias of the evidence summarisation 
processes leading to the development of PDAs.
MEthods
study design and procedures
We will develop an evidence summarisation process 
specific to PDA development by using a consensus-based 
Delphi approach previously used in the development 
of a quality criteria framework for PDAs.2 19 Consensus 
methods can harness the views of international experts 
on a wide range of information and questions in order to 
make decisions that are based on expert consensus.20 We 
will conduct a multi-round modified Delphi survey (two 
to three rounds). Compared with the nominal group 
technique, it is the most practical and scalable method 
to obtain feedback from a large number of stakeholders 
in different geographical locations. During the multiple 
rounds of online questionnaires, relevant stakeholders 
will be consulted to provide feedback about the evolving 
set of evidence summarisation steps and criteria. The 
anonymous responses from participants will be fed back 
to them in subsequent rounds. Depending on the level of 
consensus after two rounds (see Data analysis section), we 
will determine whether to conduct a third survey round.
study management
To oversee the tasks of (1) generating an initial set of 
criteria for the Delphi process and (2) managing the 
Delphi survey distribution and analysis, we convened 
a steering group. This group will oversee the project 
and will make strategic decisions about the study 
design, data collection and analysis processes, as well 
as agree on a final process and related set of steps and 
criteria. An invitation to join this group was posted 
on social media (Shared@Shared Decision Making 
Network Facebook group: 745 members) on 30 June 
2017. The post invited all Facebook group members to 
join an in-person meeting about evidence summarisa-
tion during the International Shared Decision Making 
conference held in Lyon, France, between 2 July and 
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5 July 2017. For those who were not able to join the 
meeting but expressed an interest in evidence summari-
sation of PDAs, a high-level summary was posted on Face-
book. The steering group was convened in September 
2017. The study steering group includes nine interna-
tional experts in PDA development, evaluation and 
implementation, evidence summarisation and clinical 
practice guidelines, and one patient representative. 
Six steering group members are based in the USA, one 
in Canada, one in Australia and one in Spain. Google 
Drive and video-conferencing facilities will be used to 
facilitate the exchange and review of information and 
documents, virtual meetings, as well as real-time collab-
oration and version-control.
Participants
To maximise the generalisability and applicability of 
the criteria, we plan to invite for participation in the 
survey members of the following groups: (1) all known 
developers of PDAs who created or updated a tool 
within the last five calendar years (using existing inven-
tory), (2) all members of the of the IPDAS group, (3) 
the shared decision making listserv, (4) the Society for 
Participatory Medicine listserv, (5) an overdiagnosis 
Google group, (6) the evidence-based healthcare list-
serv, (7) the Society for Medical Decision Making, (8) 
the Society of Behavioural Medicine (Health Decision 
Making Interest Group), (9) HTAi-ISG patient involve-
ment listserv, (10) GRADE working group, (11) the 
Guidelines International Network, (12) convenience 
sample of policy makers with interest and expertise in 
PDA certification, (13) the BMJ patient group and (14) 
the ProPublica Patient Safety Community. We have no 
other eligibility criteria (except for membership of one 
of the above listed groups).
For all participants, the survey invitation (supplemen-
tary file 1) will provide a brief outline of the study, a link 
to the online survey (supplementary file 2), and a brief 
participant information sheet as the first page of the survey. 
Consent will be inferred by participants’ completion of 
the survey. The ethics application form and protocol were 
submitted to Dartmouth College’s committee for the 
protection of human subjects on 27 April 2018. Approval 
was granted on 23 May 2018 (STUDY00031042).
In order not to contaminate the Delphi survey results 
and express their views twice (in developing the orig-
inal items and taking the surveys), the steering group 
members have unanimously decided not to complete the 
Delphi surveys.
Patient and public involvement
Design
Our patient partner, SC, was involved in the development 
of the Delphi survey and provided meaningful feedback 
on iterative drafts of the online questionnaire. SC is a 
core member of our study steering group and an author 
on this manuscript.
Participants
We also plan to make a concerted effort to recruit patient 
participants. We will reach out to online patient groups, 
including the BMJ patient group and the ProPublica 
Patient Safety Community (more than 6000 members). 
We will also engage a patient and family advisor group at 
Dartmouth-Hitchcock Medical Center.
Analysis
Our patient partner will be a critical part of our analysis 
team, and will be involved in all steering group meetings.
survey development
The main output of the original Lyon evidence summari-
sation meeting was the creation of a spreadsheet that 
detailed all evidence-summarisation steps inherent to 
PDA development. The first draft of this spreadsheet, 
iteratively developed by the steering group members, 
included 18 criteria. Combining those 18 criteria with the 
eight existing standards for the summarisation of clinical 
practice guidelines as outlined by the National Academy 
of Medicine (formerly IOM) & US Preventive Services 
Task Force Standards led to the creation of the first draft 
of the proposed process and steps. This draft was shared 
in a Google doc with all members of the steering group 
and iteratively refined and finalised. Three separate iter-
ations of the process (phases, steps and criteria) were 
created, reviewed and discussed by the steering group 
members until no additional revisions were suggested. A 
final internal version of the criteria (n=48), categorised 
into four phases and 13 steps was finalised in April 2018 
(see supplementary file 3).
data collection
Round 1 survey
The round 1 survey will include a brief information page 
and a summary of the process that led to the development 
of the phases, steps and criteria. Participants will be asked 
to provide their input on the phases, steps and criteria 
(including inclusion, wording, grouping, order and any 
other comments). Specifically, they will be asked to indi-
cate, using a four-point Likert Scale (omit, possible, desir-
able, essential), whether each criterion included in the 
proposed process should be omitted or kept (and whether 
it is considered possible, desirable or essential). The 
criteria will be grouped into relevant phases and steps. 
For each phase and for each step, participants will be 
given the opportunity to provide rewording suggestions, 
suggest additional phases, steps or criteria, comment 
on the order of those elements or provide additional 
comments or questions. Email addresses will be collected 
so that participants can participate in further rounds. 
At the end of each round, we will confirm participants' 
interest to participate in the next round. Participants will 
also be asked to complete basic demographic questions. 
Each round of the survey will be open for 3 weeks, and 
two reminders will be sent.
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Round 2 survey (and round 3, as necessary)
Round 1 participants will be invited to complete a second 
survey, in which feedback will be provided about the results 
of the first round (percentage of participants who thought 
a criterion should be included or excluded) and about the 
changes made based on the qualitative feedback. Partici-
pants will be invited to indicate whether to omit or include 
(omit, possible, desirable, essential) the items, including the 
new items proposed by participants in the first round, and 
to provide additional rewording suggestions, comments or 
questions. As mentioned above, the survey will be open for 
3 weeks, and two email reminders will be sent. Depending 
on the level of consensus (see data analysis section), a third 
round may be conducted. This will be determined by the 
steering group after round 2 data analysis is completed. We 
will use open debate and discussion followed by a demo-
cratic consensus.
data analysis
Following round 1, the ratings will be summarised using 
percentages and the views of all participants will be given 
equal weight. If at least 80% of participants rate an item in 
the lower two categories (omit, possible) or in the higher 
two categories (desirable, essential), we will consider 
consensus as having been achieved and the item will be 
removed or retained, respectively. Items where ratings do 
not meet the consensus threshold and conflict with open 
text comments will be grouped together and explained 
to round 2 participants. They will be asked to re-rate 
those items taking the qualitative feedback into account. 
Following the first survey round, a consensus meeting 
involving the steering group will be held. The steering 
group will review and discuss the ratings and qualitative 
feedback received, including rewording suggestions per 
criterion, suggestions to add new phases, steps or criteria 
and more general comments or questions. The wording 
or order of the phases, steps or criteria will be revised 
if two or more respondents suggest it or if the steering 
group members agree that the phase, step or criterion 
would benefit from rewording, reordering or merging.
Following the second survey round, a second consensus 
meeting will be held. Decisions on whether to conduct a 
third round and retain items in the Scale will be made 
based on the ratings in the survey rounds and feed-
back/comments from participants. The ratings will 
be summarised using percentages and the views of all 
participants will be given equal weight. If at least 80% of 
participants rate the importance of the item in the lower 
two categories, or in the higher two categories, we will 
consider consensus as having been achieved and the item 
will be removed or retained, respectively. If no consensus 
is achieved or the consensus ratings are contradicted by 
recurring open text comments, the steering group will 
decide whether or not to retain a criterion, basing this 
decision on qualitative feedback from the participants 
where possible, and the steering group’s views. We have 
successfully used this approach before.21
Only complete surveys will be included in the analysis. 
We will report the amount of missing data in the manu-
script reporting the results of the Delphi survey.
data management and safety
Data to be collected include information about the partic-
ipant’s role as it relates to PDAs, general demographics 
and their opinion of what to add/change/include in 
an evidence summarisation process. We are careful to 
protect the identity of all study participants. We will store 
the data securely in accordance with standard human 
subject research protocols. All data will be retained for 
3 years, per the Dartmouth College data retention policy 
(or for the period specified by journals in which arising 
manuscripts are published, if longer) and then destroyed 
securely.
dIsCussIon
PDAs must have accurate and trustworthy evidence-
based information about the risks and benefits of health 
treatments and tests, as these tools help patients make 
important healthcare choices. We want to generate 
consensus on an approach for selecting and summarising 
the evidence included in PDAs, which we hope can be 
widely adopted by decision aid developers.
strengths and limitations
A strength of this study is the systematic involvement 
of patients and relevant stakeholders in planning the 
modified Delphi survey. We plan to include a diverse 
sample of participant stakeholders including patients, 
researchers, PDA developers and health policy makers. 
Limitations of online surveys always include the possi-
bility of selection biases, meaning participants who opt 
to take the survey may be systematically different from 
the target population. In our case, the participants may 
be more engaged and more interested in the outcome 
of the Delphi survey. There is also a possibility that 
their views will be stronger than those who opted not 
to participate.
ConClusIon
Patients should be able to trust the information they 
receive from PDAs. Together with their clinicians, 
family and caregivers, they rely on these tools to make 
decisions that are aligned with their informed prefer-
ences. We believe standardising a process for selecting 
and summarising the evidence included in PDAs is 
therefore a worthwhile effort. Bringing all relevant 
stakeholders to the table - patients, researchers, PDA 
developers and healthcare policy makers - will ensure 
that the ultimate outcome is rigorous and rooted in 
consensus to promote widespread adoption.
Ethics and dissemination
We plan to publish our results in a peer-reviewed journal.
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